查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848613

患者来源异质骨移植/PDX模型市场按类型、肿瘤类型、研究类型、移植方法、应用和最终用户划分——2025-2032年全球预测

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，患者来源异质骨移植/PDX 模型市场将成长至 11.1282 亿美元，复合年增长率为 12.65%。

主要市场统计数据
基准年 2024 4.2904亿美元
预计年份：2025年 4.8065亿美元
预测年份：2032年 1,112,820,000 美元
复合年增长率 (%) 12.65%

本书权威地介绍了患者来源的异种移植（PDX）模型、其转化意义及其在临床前肿瘤学研究中不断演变的作用。

患者来源的异质骨移植模型在转化肿瘤学中日益重要，因为它们能够保留患者的肿瘤结构、细胞异质性以及相关的微环境相互作用。透过将新鲜的人类肿瘤组织块移植到免疫力缺乏的囓齿动物体内，研究人员可以获得保留分子特征和药物反应模式、更能代表临床疾病的模型。这种高度的相似性是PDX在药物疗效测试、作用机制研究和生物标记开发中效用的基础，从而连接了临床前试验和临床假设。

儘管PDX平台具有诸多优势，但也面临独特的操作和科学研究挑战。由于移植成功率取决于肿瘤类型和样本质量，因此需要精细的组织处理、优化的移植方法以及严格的品管基因型鉴定以防止基因漂移。此外，出于伦理考量和法律规范，必须确保人源材料的可追溯性并遵守人道动物照护标准。因此，整合手术取得、病理检查、分子分析和动物饲养的多学科工作流程对于充分发挥PDX系统的转化潜力至关重要。

随着这一领域的发展，研究人员必须权衡PDX的生物学相关性与成本、通量和可重复性等限制因素。最具影响力的项目将把标准化方案与详细的分子註释相结合，从而实现不同队列间的对照比较，并加速将临床前讯号转化为可操作的临床策略。

从先进的分子分析到新型移植技术和协作资料框架，技术和策略曲折点正在塑造PDX生态系统。

在技​​术创新与学术界、生物製药公司和委外研发机构策略重点转变的共同推动下，PDX模型领域正经历变革。高解析度分子工具，例如单细胞定序和全面的基因组分析，如今已常规应用于PDX队列，使研究人员能够揭示肿瘤内异质性并追踪不同传代过程中抗药性亚克隆的变化。同时，基因组工程和人源化免疫系统模型正在拓展PDX模型的生物学背景，尤其是在免疫肿瘤学应用方面。

在营运层面，已发生显着转变，从孤立的内部项目转向整合生物样本库、分子表征和纵向体内试验的综合平台。这种整合因对原位移植和复杂移植策略日益增长的需求而得到加强，这些策略旨在更好地模拟肿瘤-基质相互作用和转移行为。同样重要的是，数位基础设施和资料共用框架正在日趋成熟，从而能够进行跨中心的比较分析，并支持进行队列研究的合作方法。

这些转变将提升PDX模型的转化价值，同时重塑服务模式、伙伴关係结构与竞争动态。那些将技术严谨性与可互通的资料实践和标靶化的临床转换管道结合的机构，将定义下一代临床前风险规避策略。

美国近期于2025年实施的关税将如何改变PDX供应链、采购经济以及整个临床前测试生态系统的策略采购决策？

2025年的关税环境为依赖全球供应链维持其PDX计画的机构带来了一系列新的营运考量。关税主导进口实验室设备、专用耗材和某些动物品系的到岸成本上涨，加速了采购审查进程，迫使许多机构重新评估筹资策略。这促使研究团队和采购专家重新评估外部供应商的总拥有成本，并更重视前置作业时间和海关相关因素带来的不确定性。

因此，一些研究机构正在加快对国内育种和冷冻保存能力的投资，以降低跨境关税和物流中断的风险。这种近岸外包趋势能够更好地控制遗传完整性和族群健康，但也需要资金投入、扩大设施容量和提升营运专业水准。同时，能够提供可替代以往进口试剂和设备的本地供应商也迎来了新的机会，使实验室能够在控制采购风险的同时，维持实验的连续性。

事实上，关税情势也加强了法律、监管和采购团队之间的合作，以确保在遵守科学时间表的同时实现合规。跨国和跨境合作越来越多地在合作伙伴之间协商风险共用通讯协定和紧急计画，以减轻关税相关的延误和价格波动对其营运的影响。最终，这些累积效应促使各方转向加强供应链韧性、策略性库存管理和供应商资格认证通讯协定。

针对不同模型类型、肿瘤类别、检测方式、移植方法和最终用户需求，细分市场的具体表现和策略要务。

对细分市场的详细分析揭示了不同模型类型、肿瘤类别、研究模式、移植方法、应用领域和最终用户之间存在的差异化需求和性能驱动因素。小鼠和大鼠模型之间的模型类型差异，包括移植率、免疫相容性以及对特定外科手术或原位移植的适用性，会影响实验设计，从而为疗效或转移研究的选择标准提供基础。消化器官系统、妇科、血液学、呼吸系统和泌尿器官系统类别内部的肿瘤异质性会影响检体的可用性、移植倾向以及解读转化讯号所需的分子註释程度。

体外、离体或体内测试方法的选择决定了PDX资源的利用方式。离体和体外试验透过机制阐明和中型通量筛检，对体内疗效测试起到补充作用，而体内测试对于药物动力学和肿瘤微环境评估至关重要。植入方法（异位、原位或皮下）的选择直接影响转化相关性和通量考量。原位植入通常能获得更具临床意义的转移和微环境表型，而皮下植入则可实现更高的通量和标准化测量。

这些应用涵盖基础癌症研究、生物标记发现、基因组和分子研究、个人化医疗、临床前药物评估以及肿瘤微环境分析，每项应用都有其独特的数据、註释和样本处理要求。最后，包括学术研究机构、癌症研究中心和製药生物技术公司在内的最终用户在通量、监管可追溯性和商业性保密性方面有着不同的优先事项，从而塑造了整个生态系统的服务模式和伙伴关係结构。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和竞争地位如何影响市场准入、监管和研究伙伴关係

区域动态对PDX资源的取得、监管预期和合作研究网络有显着影响。美洲地区拥有高度集中的转化肿瘤学专业知识、密集的学术中心和生物技术公司网络，并务实地致力于将PDX模型整合到临床转化流程中。这种环境有利于临床前讯号与早期临床试验之间的快速迭代，同时也推动了对可靠的分子註释和高品质生物检体的需求。

欧洲、中东和非洲的监管环境各不相同，但都拥有广泛的公共研究基础设施。广泛地区合作和联盟是协调人体组织使用和动物福利标准以及汇集罕见肿瘤资源的常用机制。此类伙伴关係通常优先考虑标准化操作规程和跨中心检验，以确保多中心临床前计画具有较高的外部效度。

亚太地区产能快速扩张，国内实验室设备和动物模型供应商数量不断增加。对本地繁殖设施的投资，以及在特定肿瘤适应症领域强劲的临床研究活动，使该地区成为服务市场和新型患者来源材料的来源。在所有地区，监管的一致性、数据的互通性和供应商合格都是提高PDX研究可重复性和实用性的关键因素。

在PDX模型格局中，企业定位、联盟模式和能力投资共同决定了相关人员之间的竞争优势。

在PDX（病患来源异种移植）研究领域，各机构之间的竞争动态日益受到能力广度、分子註释深度以及提供端到端转化服务能力的影响。领先的研发机构和科研计画正投资于整合生物样本库、基因组表征和纵向体内试验的综合服务，以缩短药物研发公司的决策週期。学术中心与商业实验室之间的策略伙伴关係，在扩大获取註释丰富的队列资料的同时，也分摊了模型维护的成本和营运负担。

另一个值得关注的趋势是数据资产的优先化。能够整合可互通的分子、表型和治疗反应资料集的机构，可以进行比较分析和预测建模，从而创造差异化价值。同时，那些拥有严格的品管流程和透明的人类来源样本来源的机构，能够确保获得监管机构和伦理监督机构的信任。此外，提供可扩展的原位建模、免疫人源化和专业移植技术的供应商，正在开闢与特定治疗模式（例如免疫肿瘤学或转移性疾病治疗）相契合的利基市场。

总而言之，这些策略倡议凸显了PDX领域的竞争优势在于那些能够将科学严谨性、营运可扩展性和强大的资料管理能力结合起来的人。

为产业领导者提供实际、影响深远的行动方案，以增强供应链韧性、加速转化价值并优化临床前试验结果

产业领导者可以采取以下几项具体措施来增强转换应用的影响力和营运韧性。首先，优先投资国内族群管理和冷冻保存基础设施，以维持遗传完整性，同时减少跨境干扰。其次，将组织获取、移植和分子表征的统一通讯协定製度化，以提高可重复性并实现有意义的队列间比较。第三，将全面的基因组和单细胞分析整合到基准表征工作流程中，以便在分子层次上解读体内讯号。

第四，我们将与专业供应商建立策略伙伴关係，以便在无需承担资本和营运成本的情况下，取得他们在同位素和人源化模型方面的专业知识。第五，我们将采用联邦资料架构和标准化元资料模式，以促进各研究机构间安全的资料共用和比较分析。第六，我们将积极与监管机构和伦理委员会沟通，履行合规义务，并为转化研究建立切实可行的人体组织使用和动物福利框架。最后，我们将开发支援转换终点的商业模式，提供包括生物银行、分子註释、体内测试和资料提供在内的捆绑式服务，从而减少使用者操作障碍，加快决策速度。

采用透明、多学科的研究途径，结合主要相关人员访谈、技术检验和结构化证据综合，确保分析的严谨性。

本研究综合分析采用多学科方法，整合了来自同行评审文献、方案库以及对转化科学家、实验室人员、采购专家和合约研究组织（CRO）高管的结构化访谈的证据。主要资料透过半结构化访谈收集，以了解实际营运、痛点和策略重点，并将这些定性见解与技术文献和程序标准检验，以确保科学准确性。

此外，我们还进行了一项技术检验，审查了具有代表性的PDX方案和标註方法，以评估可重复性风险和资料互通性。我们采用分割方法，将模型类型、肿瘤类别、研究模式、移植方法、应用领域和最终用户画像进行映射，明确功能需求和服务缺口。在整个过程中，我们进行了品质保证检查，以确认所引用方法的来源以及所参考的监管和伦理指南的时效性。

这些进展包括对持续技术发展和不断变化的政策环境的敏感性。因此，本研究强调可调整的建议，并鼓励定期重新评估。此调查方法框架可支持可重复的更新，并且可以进行调整以纳入新的原始数据，以及对特定肿瘤类型和地理的更深入研究。

全面深入了解决定PDX倡议近期发展轨迹和转化成功的科学、运营和政策因素。

摘要：当患者来源的异种移植模型被整合到严谨的分子表征流程中，并由稳健的运作系统进行管理时，它们仍然是转化肿瘤学的基石。单细胞分析、免疫人源化和原位建模的科学进步正在提高PDX平台的转化保真度，而供应链压力和采购经济的变化正在促使策略转向国内能力建设和区域伙伴关係。

为了充分发挥PDX方法的潜力，相关人员必须权衡生物学相关性与通量、成本和可重复性等因素。标准化通讯协定、可互通的资料实践以及能够分担基础设施负担的协作模式将是这项工作的核心。最终，那些能够将卓越的技术与策略供应链计划和清晰的转化路径相结合的机构，将最有能力将临床前研究成果转化为临床成功。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人源化免疫系统整合到PDX模型中，以优化免疫治疗反应
  • 透过在PDX模型中应用CRISPR基因编辑技术加速个人化肿瘤药物筛检
  • 采用高通量自动化PDX平台进行大规模临床前药物评价
  • 生物製药公司和合约研究组织 (CRO) 合作，以实现 PDX 模型品管和可重复性的标准化。
  • 发展类器官衍生的异种移植模型以补充异质性肿瘤的PDX研究
  • 利用PDX模型中的多组体学分析鑑定标靶治疗的预测性生物标记
  • 扩大PDX生物样本库，纳入不同种族和罕见癌症亚型，以供全球研究使用。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 病人来源异质骨移植/PDX模型市场（按类型划分）

  • 小鼠模型
  • 大鼠模型

9. 依肿瘤类型分類的病人来源异质骨移植/PDX模型市场

  • 消化器官系统
  • 妇科
  • 血液学
  • 呼吸系统
  • 泌尿系统

10. 依研究类型分類的病人来源异质骨移植/PDX模型市场

  • 体外
  • 体外
  • 体内

11. 依移植方法分類的病人来源异质骨移植/PDX模型市场

  • 异位
  • 共形主题
  • 皮下

12. 按应用分類的患者来源异质骨移植/PDX模型市场

  • 基础癌症研究
  • 生物标记发现
  • 基因组和分子研究
  • 个人化医疗
  • 临床前药物评价
  • 肿瘤微环境分析

13. 依最终使用者分類的病患来源异质骨移植/PDX模型市场

  • 学术研究机构
  • 癌症研究中心
  • 製药和生物技术公司

14. 各地区病患来源异质骨移植/PDX模型市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 病人来源异质骨移植/PDX模型市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国患者来源异质骨移植移植/PDX模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abnova Corporation
    • Altogen Labs
    • Biocytogen
    • BioDuro LLC
    • BioReperia AB
    • Certis Oncology Solutions
    • Champions Oncology, Inc.
    • Charles River Laboratories International, Inc.
    • Creative Animodel
    • Creative Biolabs
    • Crown Bioscience by JSR Corporation
    • EPO Berlin-Buch GmbH
    • GemPharmatech Co. Ltd.
    • Genesis Drug Discovery & Development
    • Hera Biolabs
    • HOIST Co.,Ltd.
    • InnoSer
    • Inotiv, Inc.
    • Laboratory Corporation of America Holdings
    • LIDE Shanghai BIoTech, Ltd
    • Mediford Corporation by PHC Holdings Corporation
    • Oncodesign Services
    • Shanghai ChemPartner
    • Shanghai Medicilon Inc.
    • TheraIndx Lifesciences Pvt. Ltd.
    • Urosphere SAS
    • WuXi AppTec Co., Ltd.
    • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market is projected to grow by USD 1,112.82 million at a CAGR of 12.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 429.04 million
Estimated Year [2025] USD 480.65 million
Forecast Year [2032] USD 1,112.82 million
CAGR (%) 12.65%

An authoritative primer on patient-derived xenograft (PDX) models, their translational relevance, and evolving role in preclinical oncology research

Patient-derived xenograft models are increasingly central to translational oncology as they preserve patient tumor architecture, cellular heterogeneity, and relevant microenvironmental interactions that are often lost in long-established cell lines. By engrafting fresh human tumor fragments into immunocompromised rodents, researchers obtain models that retain molecular signatures and drug response patterns more representative of clinical disease. This fidelity underpins their utility across drug efficacy testing, mechanism-of-action studies, and biomarker development, providing a bridge between preclinical exploration and clinical hypotheses.

Despite their strengths, PDX platforms present distinct operational and scientific challenges. Engraftment success varies by tumor type and specimen quality, requiring refined tissue handling, optimized implantation methods, and rigorous quality-control genotyping to guard against drift. Moreover, ethical considerations and regulatory oversight demand traceability of human-derived materials and adherence to humane animal care standards. Consequently, multidisciplinary workflows that integrate surgical retrieval, pathology review, molecular profiling, and animal husbandry are essential to realize the translational promise of PDX systems.

As the field advances, investigators must balance the high biological relevance of PDX with cost, throughput, and reproducibility constraints. The most impactful programs are those that combine standardized protocols with deep molecular annotation, enabling controlled comparisons across cohorts and accelerating the translation of preclinical signals into actionable clinical strategies.

Technical and strategic inflection points reshaping the PDX ecosystem from advanced molecular profiling to novel engraftment techniques and collaborative data frameworks

The PDX landscape is undergoing transformative shifts driven by converging technological innovations and changing strategic priorities across academia, biopharma, and contract research organizations. High-resolution molecular tools such as single-cell sequencing and comprehensive genomic profiling are now routinely layered onto PDX cohorts, enabling researchers to dissect intratumoral heterogeneity and trace resistant subclones across passages. Concurrently, genome engineering and humanized immune system models are expanding the biological contexts in which PDX models can be interrogated, particularly for immuno-oncology applications.

Operationally, there is a pronounced move from isolated in-house programs toward integrated platforms that combine biobanking, molecular characterization, and longitudinal in vivo testing. This integration is reinforced by increased demand for orthotopic engraftment and sophisticated implantation strategies that better recapitulate tumor-stroma interactions and metastatic behavior. Equally important, digital infrastructure and data-sharing frameworks are maturing, allowing comparative analyses across institutions and enabling federated approaches to cohort discovery.

Together, these shifts amplify the translational value of PDX models while reshaping service models, partnership structures, and competitive dynamics. Organizations that align technical rigor with interoperable data practices and targeted clinical translation pathways will define the next generation of preclinical de-risking strategies.

How recent United States tariffs in 2025 are altering PDX supply chains, procurement economics, and strategic sourcing decisions across the preclinical ecosystem

The tariff environment introduced in 2025 has created a new set of operational considerations for organizations that rely on global supply chains to maintain PDX programs. Tariff-driven increases in the landed cost of imported laboratory equipment, specialized consumables, and certain animal strains have accelerated procurement reviews and prompted many groups to reevaluate sourcing strategies. In response, research teams and procurement specialists are reassessing the total cost of ownership for external suppliers and increasing scrutiny of lead times and customs-related variability.

Consequently, some institutions are accelerating investments in domestic breeding and cryopreservation capacity to reduce exposure to cross-border tariffs and logistic disruptions. This nearshoring trend enhances control over genetic integrity and colony health, but it requires capital allocation, expanded facility capability, and operational expertise. At the same time, there are emerging opportunities for regional vendors that can offer validated alternatives to previously imported reagents and equipment, enabling laboratories to maintain experimental continuity while managing procurement risk.

Practically, the tariff landscape has also intensified collaboration between legal, regulatory, and procurement teams to ensure compliance while preserving scientific timelines. For multinational studies and cross-border collaborations, partners are increasingly negotiating shared risk protocols and contingency plans to mitigate the operational impact of tariff-related delays and price volatility. Ultimately, the cumulative effect is a reorientation toward supply chain resilience, strategic inventory management, and strengthened supplier qualification protocols.

Segment-specific performance and strategic imperatives across model types, tumor categories, study modalities, implantation approaches and end-user demands

A granular view of segmentation reveals differentiated needs and performance drivers across types of models, tumor classes, study modalities, implantation approaches, applications, and end users. Model type distinctions between Mice Models and Rat Models shape experimental design through differences in engraftment rates, immune compatibility, and suitability for specific surgical or orthotopic procedures, thereby informing selection criteria for efficacy or metastasis studies. Tumor heterogeneity across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological categories influences specimen availability, engraftment propensity, and the degree of molecular annotation required to interpret translational signals.

Study type choices among Ex-vivo, In-vitro, and In-vivo modalities determine how PDX resources are leveraged: ex-vivo and in-vitro assays complement in-vivo efficacy testing by enabling mechanistic interrogation and medium-throughput screening, while in-vivo studies remain essential for pharmacokinetic and tumor microenvironment assessments. Implantation method selection-whether Heterotopic, Orthotopic, or Subcutaneous-directly impacts translational relevance and throughput considerations; orthotopic approaches often yield more clinically relevant metastatic and microenvironmental phenotypes, while subcutaneous implants can offer higher throughput and standardized measurement.

Applications span Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis, each imposing unique data, annotation, and sample handling requirements. Finally, end users such as Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies bring divergent priorities around throughput, regulatory traceability, and commercial confidentiality, which in turn shape service models and partnership structures across the ecosystem.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa and Asia-Pacific influencing access, regulation and research partnerships

Regional dynamics are exerting a strong influence on access to PDX resources, regulatory expectations, and collaborative networks. In the Americas, there is significant concentration of translational oncology expertise, dense networks of academic centers and biotechs, and a pragmatic focus on integrating PDX models into clinical translational pipelines. This environment supports fast iteration between preclinical signals and early-phase clinical testing, while simultaneously driving demand for robust molecular annotation and high-quality biobanked specimens.

Europe, Middle East & Africa feature a heterogeneous regulatory landscape and a broad range of public research infrastructures. Pan-regional collaborations and consortia are common mechanisms to harmonize standards for human tissue use and animal welfare, and to pool rare tumor resources. These partnerships often prioritize standardized operating procedures and cross-site validation to enable multi-center preclinical programs with higher external validity.

The Asia-Pacific region combines rapid capacity expansion with growing domestic suppliers of laboratory equipment and animal models. Investment in local breeding facilities, coupled with strong clinical research activity in specific oncology indications, positions the region as both a market for services and a source of novel patient-derived material. Across all regions, regulatory alignment, data interoperability, and supplier qualification remain critical enablers of reproducible and translatable PDX-based research.

Corporate positioning, partnership patterns, and capability investments that define competitive advantage among stakeholders in the PDX model landscape

Competitive dynamics among organizations involved in PDX research are increasingly shaped by capability breadth, depth of molecular annotation, and the ability to offer end-to-end translational services. Leading providers and institutional programs are investing in integrated offerings that combine biobanking, genomic characterization, and longitudinal in vivo testing to shorten decision cycles for drug developers. Strategic partnerships between academic centers and commercial laboratories are expanding access to richly annotated cohorts while distributing the cost and operational burden of model maintenance.

Another salient trend is the prioritization of data assets. Entities that can aggregate interoperable molecular, phenotypic, and treatment-response datasets create differentiated value by enabling comparative analyses and predictive modeling. At the same time, organizations that demonstrate rigorous quality-control pipelines and transparent provenance for human-derived materials secure trust from regulatory and ethical oversight bodies, which is increasingly material in commercial collaborations. Additionally, vendors that offer scalable orthotopic modeling, immune humanization, or specialized implantation expertise are carving niche positions that align with specific therapeutic modalities, such as immuno-oncology or metastasis-focused programs.

Collectively, these strategic moves underscore that competitive advantage in the PDX domain accrues to those who combine scientific rigor with operational scalability and robust data stewardship.

Practical, high-impact actions for industry leaders to strengthen supply resilience, accelerate translational value and optimize preclinical study outcomes

Industry leaders can take several concrete steps to enhance translational impact and operational resilience. First, prioritize investments in domestic colony management and cryopreservation infrastructure to reduce exposure to cross-border disruptions while preserving genetic fidelity. Second, institutionalize harmonized protocols for tissue procurement, implantation, and molecular characterization to improve reproducibility and enable meaningful cross-cohort comparisons. Third, integrate comprehensive genomic and single-cell profiling into baseline characterization workflows so that in vivo signals can be interpreted in a molecularly informed context.

Fourth, cultivate strategic partnerships with specialized providers to access orthotopic and humanized model expertise without bearing full capital and operational overhead. Fifth, adopt federated data architectures and standardized metadata schemas to facilitate secure data sharing and comparative analyses across institutions. Sixth, engage proactively with regulatory and ethical authorities to shape pragmatic frameworks for human tissue use and animal welfare that support translational research while meeting compliance obligations. Finally, align commercial models to support translational endpoints-offering bundled services that encompass biobanking, molecular annotation, in vivo testing, and data delivery-to reduce friction for end-users and accelerate decision-making.

Transparent multidisciplinary research approach integrating primary stakeholder interviews, technical validation, and structured evidence synthesis to ensure analytic rigor

This research synthesis is grounded in a multidisciplinary methodology that triangulates evidence from peer-reviewed literature, protocol repositories, and structured interviews with translational scientists, lab directors, procurement specialists, and CRO executives. Primary data were gathered through semi-structured interviews to capture operational realities, pain points, and strategic priorities, and these qualitative insights were validated against technical publications and procedural standards to ensure scientific accuracy.

In addition, technical validation exercises reviewed representative PDX protocols and annotation practices to assess reproducibility risk and data interoperability. The segmentation approach mapped model types, tumor classes, study modalities, implantation methods, applications, and end-user profiles to identify distinct capability requirements and service gaps. Throughout the process, quality assurance checks were performed to confirm the provenance of cited methods and the currency of regulatory and ethical guidance referenced.

Limitations include sensitivity to ongoing technological developments and evolving policy landscapes, which is why the research emphasizes adaptive recommendations and encourages periodic reassessment. The methodological framework supports reproducible updating and can be tailored to incorporate new primary data or targeted deep dives on specific tumor types or geographies.

Consolidated insights synthesizing scientific, operational and policy factors that will determine the near-term trajectory and translational success of PDX initiatives

In summary, patient-derived xenograft models remain a cornerstone of translational oncology when they are embedded within rigorous molecular characterization pipelines and managed through resilient operational systems. Scientific advances in single-cell analytics, immune humanization, and orthotopic modeling are enhancing the translational fidelity of PDX platforms, while supply chain pressures and changing procurement economics are prompting strategic shifts toward domestic capability building and regional partnerships.

To realize the full potential of PDX approaches, stakeholders must balance the need for high biological relevance with considerations of throughput, cost, and reproducibility. Standardized protocols, interoperable data practices, and collaborative models that distribute infrastructure burdens will be central to this effort. Ultimately, the organizations that align technical excellence with strategic supply chain planning and clear translational pathways will be best positioned to convert preclinical insights into clinical success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of humanized immune system mice in PDX models to optimize immunotherapy responses
  • 5.2. Application of CRISPR gene editing in PDX models to accelerate personalized oncology drug screening
  • 5.3. Adoption of high-throughput automated PDX platforms for large-scale preclinical drug evaluation
  • 5.4. Collaboration between biopharma and CROs to standardize PDX model quality control and reproducibility
  • 5.5. Development of organoid-derived xenograft models to complement PDX studies in heterogenous tumors
  • 5.6. Use of multi-omics profiling in PDX models to identify predictive biomarkers for targeted therapies
  • 5.7. Expansion of PDX biobank repositories with diverse ethnic and rare cancer subtypes for global research access

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient-Derived Xenograft/PDX Model Market, by Type

  • 8.1. Mice Models
  • 8.2. Rat Models

9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 9.1. Gastrointestinal
  • 9.2. Gynecological
  • 9.3. Hematological
  • 9.4. Respiratory
  • 9.5. Urological

10. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 10.1. Ex-vivo
  • 10.2. In-vitro
  • 10.3. In-vivo

11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 11.1. Heterotopic
  • 11.2. Orthotopic
  • 11.3. Subcutaneous

12. Patient-Derived Xenograft/PDX Model Market, by Application

  • 12.1. Basic Cancer Research
  • 12.2. Biomarker Discovery
  • 12.3. Genomic & Molecular Studies
  • 12.4. Personalized Medicine
  • 12.5. Preclinical Drug Evaluation
  • 12.6. Tumor Microenvironment Analysis

13. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 13.1. Academic Research Institutes
  • 13.2. Cancer Research Centers
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Patient-Derived Xenograft/PDX Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Patient-Derived Xenograft/PDX Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Patient-Derived Xenograft/PDX Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abnova Corporation
    • 17.3.2. Altogen Labs
    • 17.3.3. Biocytogen
    • 17.3.4. BioDuro LLC
    • 17.3.5. BioReperia AB
    • 17.3.6. Certis Oncology Solutions
    • 17.3.7. Champions Oncology, Inc.
    • 17.3.8. Charles River Laboratories International, Inc.
    • 17.3.9. Creative Animodel
    • 17.3.10. Creative Biolabs
    • 17.3.11. Crown Bioscience by JSR Corporation
    • 17.3.12. EPO Berlin-Buch GmbH
    • 17.3.13. GemPharmatech Co. Ltd.
    • 17.3.14. Genesis Drug Discovery & Development
    • 17.3.15. Hera Biolabs
    • 17.3.16. HOIST Co.,Ltd.
    • 17.3.17. InnoSer
    • 17.3.18. Inotiv, Inc.
    • 17.3.19. Laboratory Corporation of America Holdings
    • 17.3.20. LIDE Shanghai Biotech, Ltd
    • 17.3.21. Mediford Corporation by PHC Holdings Corporation
    • 17.3.22. Oncodesign Services
    • 17.3.23. Shanghai ChemPartner
    • 17.3.24. Shanghai Medicilon Inc.
    • 17.3.25. TheraIndx Lifesciences Pvt. Ltd.
    • 17.3.26. Urosphere SAS
    • 17.3.27. WuXi AppTec Co., Ltd.
    • 17.3.28. Xentech

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 201